Sympathetic overdrive in patients with arterial hypertension. Myocardial remodeling

Н.Е. Айдаргалиева

2020

Full text Open access: Gold Metadata (CSL-JSON)

DOI 10.37987/1997-9894.2020.2(238).214209

Data confidence 70 medium

How this score is calculated

It is built from checkable properties of the record itself: whether the article has a DOI, how many independent sources confirmed its data, whether the required fields are filled in, and how recent the latest confirmation is. Disagreement between sources and a missing identifier lower it. A value of 80 or above means the record was published without further checking; 60 to 79 means it is published at reduced confidence, with a manual check advisable. A record verified by an editor by hand is never pushed below 90 by a recalculation. This scores our data about the article, not the article itself.

Abstract

Hyperactivation of the sympathetic nervous system (sympathetic overdrive) is the central mechanism for the development of arterial hypertension. Among antihypertensive drugs, only beta-blockers without internal sympathetic activity, for example, bisoprolol, provide complete control of sympathetic hyperactivation. Highly selective β1-adrenergic blockers inhibit sympathetic activity in the heart and kidneys, preserving β2-mediated vasodilation and reducing the risk of adverse effects due to β2-receptor blockade in the lungs and peripheral tissues.